ES2604484T3 - Formulación farmacéutica de sabor enmascarado que tiene un inicio rápido de la acción - Google Patents

Formulación farmacéutica de sabor enmascarado que tiene un inicio rápido de la acción Download PDF

Info

Publication number
ES2604484T3
ES2604484T3 ES11736275.6T ES11736275T ES2604484T3 ES 2604484 T3 ES2604484 T3 ES 2604484T3 ES 11736275 T ES11736275 T ES 11736275T ES 2604484 T3 ES2604484 T3 ES 2604484T3
Authority
ES
Spain
Prior art keywords
weight
parts
action
phosphodiesterase inhibitor
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11736275.6T
Other languages
English (en)
Inventor
Hartwig Steckel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmatech GmbH
Original Assignee
Pharmatech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmatech GmbH filed Critical Pharmatech GmbH
Application granted granted Critical
Publication of ES2604484T3 publication Critical patent/ES2604484T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición farmacéutica para la administración oral, que comprende un inhibidor de la fosfodiesterasa seleccionado entre citrato de sildenafilo y al menos un alcohol de azúcar seleccionado entre manitol, sorbitol, xilitol, maltitol, lactitol, eritritol, treitol e Isomalt e hidrógeno carbonato de sodio como excipientes farmacéuticos en las siguientes proporciones en peso: inhibidor de la fosfodiesterasa: de 10 a 150 partes en peso en total; alcohol de azúcar: de 50 a 600 partes en peso en total; hidrógeno carbonato de sodio: de 2 a 100 partes en peso; y un ácido orgánico farmacéuticamente aceptable, en la que el inhibidor de la fosfodiesterasa y el alcohol de azúcar están presentes como una mezcla de polvo o como gránulos o como una mezcla de polvo o como gránulos en un comprimido compactado, y en la que el alcohol de azúcar incluye o es Isomalt.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
Tiempo hasta el inicio de la acción [min]
Sujeto n.º
Viagra 50 mg Formulación de la invención
4
50 8
5
60 15
6
70 12
7
80 10
8
55 5
9
40 10
10
40
10
11
40 12
12
60 8
13
65 7
14
75 13
15
50 10
16
50 20
17
45 10
18
60 8
19
55 7
El sujeto 20 solo tomó la "muestra de Viagra" y después dejó la observación.
Se confirmó por 5 sujetos un mejor enmascaramiento del sabor amargo frente a una formulación comparativa que incluía solamente Isomalt.
8

Claims (1)

  1. imagen1
ES11736275.6T 2010-06-24 2011-06-24 Formulación farmacéutica de sabor enmascarado que tiene un inicio rápido de la acción Active ES2604484T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102010024866 2010-06-24
DE102010024866A DE102010024866A1 (de) 2010-06-24 2010-06-24 Formulierung zur Geschmacksmaskierung
PCT/EP2011/003120 WO2011160849A1 (en) 2010-06-24 2011-06-24 Taste-masked pharmaceutical formulation having accelerated onset of action

Publications (1)

Publication Number Publication Date
ES2604484T3 true ES2604484T3 (es) 2017-03-07

Family

ID=44629118

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11736275.6T Active ES2604484T3 (es) 2010-06-24 2011-06-24 Formulación farmacéutica de sabor enmascarado que tiene un inicio rápido de la acción

Country Status (10)

Country Link
US (1) US20130150370A1 (es)
EP (1) EP2585041B1 (es)
JP (1) JP6013329B2 (es)
BR (1) BR112012032463A2 (es)
CA (1) CA2802604C (es)
DE (1) DE102010024866A1 (es)
EA (1) EA031697B1 (es)
ES (1) ES2604484T3 (es)
PL (1) PL2585041T3 (es)
WO (1) WO2011160849A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109221A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic New effervescent formulations comprising sweetener composition
EP2942052A4 (en) * 2013-01-07 2016-06-08 Sam A Pharm Co Ltd NEW FORMULATION OF RAPID DISSOLUTION PELLETS WITH ENHANCED SOLUBILITY
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
EP4429025A2 (en) 2020-03-24 2024-09-11 CommScope Technologies LLC Radiating elements having angled feed stalks and base station antennas including same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1217445B (it) * 1988-04-29 1990-03-22 Altergon Sa Composizione farmaceutiche orosolubili contenti acetilcisteina
US4942039A (en) * 1989-05-09 1990-07-17 Miles Inc. Effervescent analgesic antacid composition having reduced sodium content
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
AU3574500A (en) * 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
AU2001273545A1 (en) * 2000-07-19 2002-01-30 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
KR100503949B1 (ko) * 2003-04-28 2005-07-26 주식회사유한양행 염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
DE10328180A1 (de) * 2003-06-16 2005-01-13 Südzucker AG Mannheim/Ochsenfurt Verwendung von Isomalt als Präbiotikum
GB0330255D0 (en) * 2003-12-31 2004-02-04 Vectura Ltd Multiparticulate formulations for oral delivery
EP3216445A1 (en) * 2004-05-28 2017-09-13 Imaginot Pty Ltd. Oral therapeutic compound delivery system
WO2007060682A1 (en) * 2005-11-28 2007-05-31 Strides Arcolab Limited Effervescent granular formulations of antiretroviral drugs
US8642016B2 (en) * 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
KR100895942B1 (ko) * 2007-05-08 2009-05-07 조선대학교산학협력단 생약 추출물을 함유하는 구강 내 속붕해성 제제 조성물 및그의 제조 방법
WO2009007768A1 (en) * 2007-07-06 2009-01-15 Gumlink A/S Compressed tablet comprising polyol
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
WO2010044736A1 (en) * 2008-10-14 2010-04-22 Mcneil Ab Multi portion intra-oral dosage form and use thereof

Also Published As

Publication number Publication date
PL2585041T3 (pl) 2017-02-28
US20130150370A1 (en) 2013-06-13
EP2585041A1 (en) 2013-05-01
WO2011160849A1 (en) 2011-12-29
EA031697B1 (ru) 2019-02-28
CA2802604A1 (en) 2011-12-29
JP2013529605A (ja) 2013-07-22
DE102010024866A1 (de) 2011-12-29
BR112012032463A2 (pt) 2016-11-08
EP2585041B1 (en) 2016-08-31
JP6013329B2 (ja) 2016-10-25
CA2802604C (en) 2018-11-06
EA201390012A1 (ru) 2013-07-30

Similar Documents

Publication Publication Date Title
AU2014363599B2 (en) Orally disintegrating solid dosage unit containing an estetrol component
HRP20210487T1 (hr) Farmaceutski sastavi koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo
EA200901277A1 (ru) Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина
ES2604484T3 (es) Formulación farmacéutica de sabor enmascarado que tiene un inicio rápido de la acción
CA3188794A1 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
ES2383433T3 (es) Formulación farmacéutica de apomorfina para administración bucal
ES2683825T3 (es) Composición farmacéutica administrable por vía oral
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
TWI526210B (zh) Oral pharmaceutical composition
CO6280463A2 (es) Formulaciones farmaceuticas solidas que comprenden bibw 2992
AU2012276114B2 (en) Substituted cinnamamide derivative, preparation method and use thereof
AR051048A1 (es) Sustituto del azucar bajo en calorias o sin calorias, no higroscopico
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
RU2014115287A (ru) Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения
EA201170695A1 (ru) Улучшенная стабильность таблеток карбоната кальция при растворении
RU2015132902A (ru) Новый быстрорастворимый состав гранул с улучшенной растворимостью
ES2624231T3 (es) Coadyuvante de formación de comprimidos a base de lactosa y celulosa
KR20160108828A (ko) 신속하게 붕괴되는 제형 및 사용 방법
WO2014027981A2 (en) Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
EP2393478B1 (en) Taste and odor masked pharmaceutical compositions with high bioavailability
US11291701B1 (en) Orally disintegrating, sublingual and buccal formulations
JP7104039B2 (ja) 医薬組成物
AR094146A1 (es) Unidad solida con alto contenido en fexofenadina y su procedimiento de preparacion
JP6107226B2 (ja) 医薬組成物
ES2678122T3 (es) Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial